MediWound (NASDAQ:MDWD) Releases Quarterly Earnings Results

Key Points

• MediWound beat EPS expectations but missed on revenue: It reported a quarterly loss of $0.65 per share, better than the expected $0.71 loss, while revenue of $3.57 million came in well below the $6.73 million consensus estimate.
• EscharEx’s VALUE trial remains on schedule for enrollment completion by the end of Q1 2027, with top-line results expected around mid-2027 if the study design stays unchanged. Meanwhile, NexoBrid demand is growing, but sales are constrained by manufacturing capacity.
• Funding and supply uncertainties weigh on the outlook: Expanded manufacturing capacity depends on regulatory approval, targeted for the second half of 2027, and a substantial portion of anticipated 2026 revenue depends on funding for a planned U.S. facility that MediWound has not secured.

MediWound (NASDAQ:MDWD - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.06, FiscalAI reports. The company had revenue of $3.57 million during the quarter, compared to the consensus estimate of $6.73 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.

Here are the key takeaways from MediWound's conference call:

• EscharEx’s VALUE trial remains on track to complete enrollment by the end of Q1 2027, with the interim sample-size reassessment planned for that period; management expects top-line results around mid-2027 if the current study design is unchanged. The latest safety review found no concerns or need for modifications.
• NexoBrid demand and U.S. commercial activity strengthened: Vericel reported its highest quarterly revenue since launch, more than 80 centers have ordered and about 70 have reordered, and BARDA procurement began in Q3. Management said supply constraints, rather than demand, are limiting product sales.
• Global NexoBrid demand currently exceeds manufacturing capacity, and the expanded facility’s commercial supply remains subject to regulatory approval, with a target of the second half of 2027. The company is prioritizing U.S. commercial and government orders while supply remains constrained.
• Q3 revenue fell to $3.6 million from $5.4 million a year earlier, while operating loss widened to $8.5 million from $6.5 million, partly as R&D spending rose to support the VALUE trial. MediWound reported $28.4 million in cash, equivalents and deposits at quarter-end and subsequently raised $17.25 million in a public offering.
• MediWound said a substantial portion of anticipated 2026 revenue depends on funding for a planned U.S.-based manufacturing facility, but it does not know when or whether that funding will be secured. The company said this uncertainty affects its revenue outlook.

MediWound Price Performance

NASDAQ:MDWD traded down $0.70 during trading hours on Thursday, reaching $13.12. 170,225 shares of the stock were exchanged, compared to its average volume of 97,946. The firm has a 50 day moving average of $13.21 and a 200 day moving average of $15.10. The stock has a market cap of $170.63 million, a PE ratio of -7.31 and a beta of 0.07. MediWound has a twelve month low of $11.80 and a twelve month high of $19.70.

Insiders Place Their Bets

In other MediWound news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MDWD. Weiss Ratings cut MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, September 8th. TD Cowen reaffirmed a "buy" rating on shares of MediWound in a research note on Thursday, September 24th. Wall Street Zen raised shares of MediWound from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 26th. Oppenheimer reiterated an "outperform" rating and issued a $30.00 price target (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Finally, Alliance Global Partners reissued a "buy" rating on shares of MediWound in a research report on Wednesday, September 16th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $33.00.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company's products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound's lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.